Notes · Pharmacology · 30 September 2026

Anticoagulants: Warfarin Mechanism and Monitoring

Definition

• Warfarin (coumarin derivative) is an oral vitamin K antagonist used for prevention and treatment of venous thromboembolism (VTE), atrial fibrillation (AF), mechanical prosthetic valves, and certain hypercoagulable states.
• It inhibits the γ‑carboxylation of vitamin K‑dependent clotting factors II, VII, IX, X and proteins C & S, thereby impairing thrombin generation.

Epidemiology

• Over 1 million patients in the U.S. receive warfarin annually; globally > 10 million.
• Indications:
  • VTE (acute & secondary prophylaxis) – 60 % of users.
  • AF – 25 %.
  • Prosthetic heart valves – 10 %.
  • Other: antiphospholipid syndrome, mechanical devices.
• Age distribution: > 70 % are > 65 years; polypharmacy and comorbidities increase risk of complications.

Aetiology (Why Warfarin is Prescribed)

• Thrombotic disorders: DVT, PE, pulmonary embolism, stroke prevention in AF.
• Mechanical prosthetic valves: high thromboembolic risk without anticoagulation.
• Hypercoagulable states: antiphospholipid syndrome, protein C/S deficiency.
• Post‑operative prophylaxis: orthopedic and abdominal surgeries.

Pathophysiology

1. Vitamin K cycle inhibition
   • Warfarin competitively blocks vitamin K epoxide reductase complex 1 (VKORC1).
   • Depletes reduced vitamin K, preventing γ‑carboxylation of glutamate residues on clotting factors.
2. Effect on clotting factors
   • Factor VII (short half‑life) falls first → INR rises rapidly.
   • Factors II, IX, X decline over 3–5 days.
   • Protein C (short half‑life) falls early → transient hypercoagulability.
3. Clinical anticoagulant effect
   • Reduced thrombin generation → impaired fibrin clot formation.
   • Balance between anticoagulation and bleeding risk is monitored by INR.

Clinical Features (Signs of Over‑/Under‑Anticoagulation)

Investigations

• International Normalized Ratio (INR) – primary monitoring tool.
  • Target ranges:
    • VTE prophylaxis: 2.0–3.0 (2024 ISTH).
    • Mechanical valves: 2.5–3.5 (ESC 2023).
    • AF: 2.0–3.0 (ACC/AHA 2023).
• Complete Blood Count (CBC) – monitor for anemia, thrombocytopenia.
• Liver Function Tests (LFTs) – warfarin metabolism via CYP2C9.
• Genetic testing – VKORC1 and CYP2C9 polymorphisms for dose prediction (optional).
• Coagulation profile – PT/INR, aPTT (for monitoring heparin bridge).
• Drug interaction screen – review concomitant medications (antibiotics, PPIs, antiepileptics).

Management (Current Guidelines – 2024)

Initiation

1. Loading dose – 5 mg PO daily for 3 days (or 10 mg for high‑risk patients).
2. Bridge with LMWH – if INR < 2.0 after 3 days or for high‑risk patients (prosthetic valves, recent VTE).
3. First INR check – day 4–5; adjust dose to reach target by day 7–10.

Dose Adjustment

• Incremental changes – 1 mg increments for INR 1.5–2.5; 0.5 mg for INR 2.5–3.5.
• Rapid INR rise – hold dose, repeat INR in 24 h.
• Low INR – increase dose by 1 mg; if INR < 1.5, consider LMWH bridge.

Monitoring Frequency

Reversal of Over‑Anticoagulation

• Vitamin K (phytonadione) – 5 mg IV/IM for INR > 10 or major bleeding.
• FFP – 10 mL/kg for INR > 5 with bleeding.
• Prothrombin complex concentrate (PCC) – 25 IU/kg for rapid reversal (esp. intracranial).
• Tranexamic acid – adjunct for mucosal bleeding.

Switching to DOACs

• Consider DOACs (apixaban, rivaroxaban) if:
  • No mechanical valve.
  • No severe renal dysfunction (CrCl > 30 mL/min).
  • Patient preference for no INR monitoring.

Complications

• Bleeding – major (intracranial, GI) and minor (epistaxis, gum bleeding).
• Warfarin‑induced skin necrosis – rare, early onset (days 3–5) in protein C/S deficiency.
• Drug interactions – antibiotics (e.g., clarithromycin), antifungals, antiplatelets, NSAIDs, PPIs.
• Teratogenicity – avoid in pregnancy; switch to heparin.
• Adherence issues – dietary vitamin K variability, forgetfulness.
• Laboratory pitfalls – lupus anticoagulant can falsely elevate INR.

High‑Yield Exam Points

• INR target ranges differ by indication; remember 2.5–3.5 for mechanical valves.
• VKORC1 & CYP2C9 polymorphisms explain inter‑individual dose variability.
• Protein C/S deficiency → early warfarin‑induced skin necrosis; treat with heparin bridge.
• Reversal agents: PCC > FFP for rapid reversal; vitamin K for sustained effect.
• Monitoring schedule: 3–4 days during initiation; 4 weeks once stable.
• Drug interactions: antibiotics ↑ warfarin effect; PPIs ↓ absorption.
• Pregnancy: warfarin contraindicated; use LMWH.
• DOACs vs. warfarin: DOACs have fixed dosing, no INR monitoring, but contraindicated in mechanical valves.

Practice Questions

1. A 68‑year‑old man with mechanical mitral valve replacement is started on warfarin. His INR on day 5 is 1.2. What is the most appropriate next step?
   Answer: B – Increase warfarin dose by 1 mg and repeat INR in 3 days. (Under‑anticoagulation; target 2.5–3.5)

2. Which of the following is the fastest method to reverse warfarin‑associated intracranial hemorrhage?
   A. Vitamin K 5 mg IV
   B. Fresh frozen plasma 10 mL/kg
   C. Prothrombin complex concentrate 25 IU/kg
   D. Tranexamic acid 1 g IV
   Answer: C – PCC provides rapid INR correction (within 15 min).

3. A patient on warfarin develops a painful, purple rash on the thighs 4 days after dose initiation. Which laboratory test is most likely to be abnormal?
   A. Elevated fibrinogen
   B. Low protein C activity
   C. High platelet count
   D. Elevated D‑dimer
   Answer: B – Low protein C activity explains warfarin‑induced skin necrosis.

More in Pharmacology

AI-assisted study material for exam revision. Always confirm with standard textbooks and current guidelines; not medical advice.